PROTAC/Molecular Glue Services

Viva provides global customers with a full range of PROTAC/Molecular Glue drug discovery services using the world's leading Structure-Based Drug Discovery technology. These services cover biology and chemistry, including protein preparation and crystal structure studies, screening of PROTAC/Molecular Glue, kinetic studies, drug metabolism, medicinal chemistry, Bioassay, AIDD/CADD, and other services.

  • 50+

    E3 ligases

  • 260+

    Deliveries of PROTAC / molecular glue ternary structures

Protein Preparation and Ternary Complex Structure Determination

Viva provides global customers with a full range of PROTAC/Molecular Glue drug discovery services using the world's leading Structure-Based Drug Discovery technology. These services cover biology and chemistry, including protein preparation and crystal structure studies, screening of PROTAC/Molecular Glue, kinetic studies, drug metabolism, medicinal chemistry, Bioassay, AIDD/CADD, and other services.

Using a highly efficient protein expression system and leading target protein structure research capabilities (X-ray & Cryo-EM), Viva has successfully researched over 50 E3 ligase structures and delivered over 260 PROTAC / molecular glue ternary structures. These technological advances greatly assisted customers in the subsequent in-depth optimization of PROTAC molecular structure and mechanism research. In addition, Cryo-Electron Microscopy (cryo-EM), a core technology platform we developed in recent years, serves as an essential technical tool for studying target protein-PROTAC-E3 ligase ternary complex structures. By overcoming a series of technical difficulties and with the accumulation of rich experience, Viva's Cryo-EM platform is able to successfully provide structure determination services.

 

PROTAC Molecular Structure Research Collaboration Case Study:

 

Source:Dragovich PS, et, al. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy. J Med Chem. 2021 Mar 11;64(5):2576-2607.

Source: Chung CW, et, al. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL. ACS Chem Biol. 2020 Sep 18;15(9):2316-2323.

 

ID Weak PPI Strategy (for PROTAC) Using HDX-MS

 

Online Message
After receiving your message, our professional team will contact you shortly.
  • Area of Interest

    CRO Drug R&D Services

    CDMO R&D and Production Services

    EFS Investment&Incubation Business

    Media Cooperation

    Investor Relations

    Other

    How Did You Hear About Us?

    Search Engine (Google, Bing, Yahoo, etc)

    Conferences/Events

    Social Media

    LinkedIn

    Word of Mouth

    Other

For more information about

“Protein Preparation and Ternary Complex Structure Determination”, please contact our team.

Contact Us
×
This site uses cookies and your privacy choices are important to us
We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.